EUVIMEDEUVIMED entdecken
Crossref

De-escalation from anti-CD20 to cladribine tablets in multiple sclerosis: A pilot study

Rosaria Sacco, Giulio Disanto, Emanuele Pravatà, Giulia Mallucci, Aleksandra Maleska Maceski, Jens Kuhle, Claudio Gobbi, Chiara Zecca

Multiple Sclerosis and Related Disorders · 2024

DOI: 10.1016/j.msard.2024.106145 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Multiple Sclerosis and Related Disorders, 2024. Verfasst von Rosaria Sacco und 7 weiteren Autor:innen. Beteiligte Einrichtung: Multiple Sclerosis Center (MSC), Department of Neurology, Neurocenter of Southern Switzerland, Lugano 6900, Switzerland. Hauptthemen laut MEDLINE: Cladribine. Die Arbeit wurde bisher 12-mal zitiert (Crossref) und nennt 11 Literaturangaben. Gefördert von: Merck, Merck Healthcare KGaA.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Prolonged treatment with anti-CD20 antibodies can lead to hypogammaglobulinemia and increased infection risk in multiple sclerosis (MS). We investigated switch from anti-CD20 to cladribine as a strategy to prevent immunoglobulin reduction while preserving efficacy. We prospectively analysed serum IgG, IgM, neurofilament light (NfL) and glial fibrillary acidic protein (GFAP) in 44 patients, 14 who were switched from anti-CD20 to cladribine and 30 continuing anti-CD20. Over 1 year, serum IgG, IgM, NfL and GFAP remained stable after switch and similar to patients continuing anti-CD20. More than 90 % of patients remained free of disease activity. Cladribine should be further explored as de-escalating agent from anti-CD20 in MS.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

CladribineHumansPilot ProjectsFemaleMaleAdultMiddle AgedImmunologic FactorsGlial Fibrillary Acidic ProteinNeurofilament ProteinsImmunoglobulin GImmunoglobulin MRituximabProspective StudiesMultiple SclerosisMultiple Sclerosis, Relapsing-RemittingImmunosuppressive AgentsDrug SubstitutionAntigens, CD20

Stichwörter der Autor:innen

Anti-CD20CladribineDe-escalationImmunoglobulinsNeurofilaments

Substanzen

Cladribineneurofilament protein LImmunologic FactorsGlial Fibrillary Acidic ProteinNeurofilament ProteinsImmunoglobulin GImmunoglobulin MRituximabGFAP protein, humanImmunosuppressive Agents

Autor:innen und Institutionen

  • Multiple Sclerosis Center (MSC), Department of Neurology, Neurocenter of Southern Switzerland, Lugano 6900, Switzerland.
  • Multiple Sclerosis Center (MSC), Department of Neurology, Neurocenter of Southern Switzerland, Lugano 6900, Switzerland; Faculty of biomedical Sciences, Università della Svizzera Italiana, Via Buffi 13, 6900 Lugano, Swi…
  • Department of Neurology, University Hospital and University of Basel, Basel, Switzerland; Multiple Sclerosis Centre and Research Centre for Clinical Neurimmunology and Neuroscience (RC2NB), Departments of Biomedicine an…

Förderung

  • Merck
  • Merck Healthcare KGaA

Zitieren

APA

Sacco, R., Disanto, G., Pravatà, E., Mallucci, G., Maceski, A. M., Kuhle, J., Gobbi, C., & Zecca, C. (2024). De-escalation from anti-CD20 to cladribine tablets in multiple sclerosis: A pilot study. Multiple Sclerosis and Related Disorders. https://doi.org/10.1016/j.msard.2024.106145

Vancouver

Sacco R, Disanto G, Pravatà E, Mallucci G, Maceski AM, Kuhle J, et al. De-escalation from anti-CD20 to cladribine tablets in multiple sclerosis: A pilot study. Multiple Sclerosis and Related Disorders. 2024. doi:10.1016/j.msard.2024.106145

BibTeX
@article{Sacco2024,
  author = {Sacco, Rosaria and Disanto, Giulio and Pravatà, Emanuele and Mallucci, Giulia and Maceski, Aleksandra Maleska and Kuhle, Jens and Gobbi, Claudio and Zecca, Chiara},
  title = {De-escalation from anti-CD20 to cladribine tablets in multiple sclerosis: A pilot study},
  journal = {Multiple Sclerosis and Related Disorders},
  year = {2024},
  doi = {10.1016/j.msard.2024.106145}
}
Kostenlos starten →